Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data and AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma and Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / App Notes / 2022 / Analytix Reporter Pharma Edition - MilliporeSigma

Analytix Reporter Pharma Edition - MilliporeSigma

09/08/2022

Share

Featured Image

Dear Reader,

Over the past several years, biologics have continued to make up an increasing proportion of biopharmaceutical sales and pipeline candidates. Biologics now account for more than half of the top selling drugs by revenue. In fact, 2018 saw a record 17 biologics license application (BLA) approvals and the 5-year annual average has more than doubled over the last decade. This trend is expected to continue for the foreseeable future with many different modalities of biologics in preclinical and clinical development. Currently, most global pharmaceutical companies’ pipelines consist of 20-40% biologics; the tipping point to a majority biologics pipeline is expected this decade. But relative to synthetic small molecule therapeutics, the manufacturing process for biologics is far more complicated and requires the use of more intense characterization, from even the earliest stages of development through production and QA/QC to ensure safety and effectiveness. While liquid chromatography/mass spectrometry (LC/MS) has always had an important role in small molecule pre-clinical animal studies and in human clinical studies, expanded use is realized both upstream into target identification and downstream into manufacturing and QC release testing with biologics.

Just some of the characterization of biologics being performed in the LC-MS lab include: intact mass, glycan analysis, peptide mapping, impurity and degradant identity, and bioanalytical assays for DMPK purposes. Beyond the capabilities of the mass spectrometer, consumables suppliers are now introducing novel sample preparation tools as well as isotopically labeled and certified reference standards for the biologics market. Specifically, for preclinical analysis of monoclonal antibodies, the introduction of immunoaffinity capture and release sample preparation kits are becoming popular. Furthermore, chromatography solvents and columns are tailored to meet the needs of large biologics. This trend includes large pore size (1000 A) chromatography columns, smaller particles and smaller internal diameter columns all designed to couple biologics separations with mass spectrometers. Improvements include improved peak shape and faster analysis. Ultra-pure LC-MS solvents have been introduced to minimize unwanted fragmentation or ionization.

My expectation is that as biologics continue towards being a majority modality in the pharmaceutical pipeline, new and unique LC-MS tools will become available for use from discovery through QC.

Sincerely yours,

Wayne Way
Pharma QC Strategic Marketing Manager

>> Download the Application Note as a PDF

Newsletters

Receive the latest analytical scientist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Analytical Science

Dive deeper into the analytical science. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Optimizing metal powders for Isostatic Pressing
Optimizing metal powders for Isostatic Pressing

January 4, 2022

Isostatic pressing has several benefits over the c...

Monitoring respirable silica at workplace
Monitoring respirable silica at workplace

January 5, 2022

Stringent regulations of occupational exposure to ...

Analytical toolkit for the optimization of battery electrode materials
Analytical toolkit for the optimization of battery electrode materials

January 7, 2022

Modern batteries like lithium-ion have revolutioni...

Analysis of catalytic ink for proton exchange membrane fuel cells (PEMFC’s)
Analysis of catalytic ink for proton exchange membrane fuel cells (PEMFC’s)

January 10, 2022

Catalytic inks are the key component when balancin...

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.